Last 47 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 21.85 | 0.68 | 1.29 | 0.24 | 0.20 | 0.22 | 0.17 | 0.23 | 0.26 | 0.23 | 0.23 | 0.21 | 0.19 | 0.04 | 0.05 | 0.03 | 0.04 | 0.04 | 0.53 | 0.08 | 0.05 |
| — | +206.7% | +648.3% | +3.7% | -23.2% | -3.3% | -26.2% | +10.8% | +40.2% | +509.4% | +373.4% | +509.4% | +381.0% | -3.4% | -90.7% | -55.2% | -28.3% | -63.7% | +474.7% | -97.4% | -28.0% | |
| P/S Ratio | 2.78 | 0.04 | 0.04 | 0.03 | 0.03 | 0.04 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 3.35 | 0.04 | 3.10 | 0.03 | 2.76 | 0.04 | 3.21 | 0.05 | 3.48 |
| — | +1.4% | +17.1% | -14.9% | -20.0% | -11.5% | -25.1% | -2.0% | -98.8% | +6.2% | -98.6% | +26.5% | +21.5% | -11.7% | -3.5% | -37.8% | -20.9% | -28.9% | -18.4% | -15.0% | -20.7% | |
| P/B Ratio | 2.63 | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 | 0.03 | 0.04 | 0.04 | 0.04 | 0.04 | 3.61 | 0.04 | 0.04 | 0.04 | 3.23 | 3.44 | 3.63 | 3.69 | 4.26 | 4.37 |
| — | -11.9% | -5.0% | -24.0% | -24.9% | -18.0% | -25.2% | -98.9% | -2.7% | +0.7% | +6.2% | +11.5% | -98.7% | -98.8% | -98.9% | -24.0% | -21.4% | -28.8% | -14.5% | -16.8% | -15.3% | |
| P/FCF | 30.56 | — | 0.27 | 0.82 | 0.54 | 0.70 | 0.26 | — | 2.36 | 1.53 | 41.95 | 407.75 | 0.20 | — | 0.15 | 0.11 | 0.37 | — | 0.46 | 0.21 | — |
| — | — | +5.1% | — | -77.3% | -54.5% | -99.4% | — | +1082.3% | — | +28089.2% | +381782.2% | -45.5% | — | -67.3% | -49.5% | — | — | -98.0% | -99.9% | — | |
| EV / EBITDA | 14.77 | 6.13 | 2.95 | 0.79 | 0.67 | 0.59 | 0.49 | 0.55 | 0.59 | 0.44 | 0.34 | 0.14 | 12.39 | 0.20 | 22.31 | 0.11 | 9.28 | 0.15 | 15.31 | 0.22 | 15.40 |
| — | +944.8% | +506.8% | +42.1% | +14.0% | +32.5% | +44.2% | +296.8% | -95.3% | +120.6% | -98.5% | +25.8% | +33.6% | +29.6% | +45.7% | -50.5% | -39.8% | -53.1% | -18.7% | -59.8% | -14.6% | |
| EV / EBIT | 21.32 | 6.13 | 5.84 | 1.05 | 0.78 | 0.66 | 0.52 | 0.66 | 0.63 | 0.54 | 0.38 | 0.16 | 11.67 | 0.24 | 26.10 | 0.13 | 10.80 | 0.16 | 66.50 | 0.28 | 16.24 |
| — | +833.8% | +1022.0% | +57.6% | +23.6% | +22.2% | +37.5% | +321.5% | -94.6% | +122.7% | -98.5% | +20.8% | +8.1% | +53.1% | -60.8% | -52.7% | -33.5% | -61.8% | +119.9% | -25.1% | -35.3% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 52.8% | 46.5% | 44.8% | 53.6% | 54.7% | 56.9% | 55.6% | 58.7% | 59.6% | 60.4% | 58.6% | 58.5% | 56.4% | 58.7% | 57.2% | 59.2% | 59.1% | 49.9% | 52.9% | 53.8% | 53.4% |
| — | -18.3% | -19.3% | -8.6% | -8.3% | -5.8% | -5.1% | +0.3% | +5.8% | +2.9% | +2.4% | -1.2% | -4.6% | +17.7% | +8.1% | +10.1% | +10.6% | -4.5% | -1.5% | -0.1% | +5.9% | |
| Operating Margin | 13.8% | 3.7% | 0.6% | 16.3% | 19.9% | 20.5% | 20.7% | 22.4% | 21.9% | 23.4% | 21.1% | 23.9% | 21.1% | 26.2% | 20.1% | 24.3% | 25.1% | 23.4% | 16.1% | 17.4% | 18.0% |
| — | -82.1% | -97.0% | -27.2% | -9.2% | -12.5% | -1.8% | -6.4% | +3.7% | -10.7% | +5.2% | -1.4% | -15.8% | +11.8% | +24.8% | +39.8% | +39.4% | +74.3% | +10.0% | +289.2% | -1.8% | |
| Net Margin | 12.8% | 5.5% | 2.9% | 13.9% | 16.3% | 16.6% | 18.7% | 16.9% | 15.7% | 18.1% | 18.5% | 19.1% | 21.5% | 20.8% | 15.2% | 18.4% | 17.6% | 22.8% | 1.6% | 13.3% | 17.2% |
| — | -66.9% | -84.4% | -18.0% | +4.2% | -8.5% | +1.5% | -11.5% | -27.2% | -12.8% | +21.1% | +3.8% | +21.9% | -8.6% | +846.5% | +38.7% | +2.5% | +96.3% | -79.0% | +3206.1% | +10.6% |
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 12.7% | 1.2% | 0.6% | 3.3% | 4.0% | 4.1% | 4.8% | 4.5% | 4.2% | 4.8% | 9.2% | 10.8% | 0.1% | 5.9% | 0.1% | 479.9% | 5.5% | 470.2% | 0.5% | 280.7% | 5.5% |
| — | -71.4% | -87.7% | -26.8% | -3.4% | -15.2% | -47.5% | -58.4% | +5690.0% | -17.8% | +9130.2% | -97.8% | -98.7% | -98.7% | -78.2% | +71.0% | +0.1% | +96.2% | -78.4% | +3131.6% | +17.5% | |
| ROA | 8.5% | 0.8% | 0.4% | 2.2% | 2.7% | 2.8% | 3.3% | 3.0% | 2.8% | 3.5% | 6.7% | 7.8% | 0.1% | 4.3% | 0.1% | 341.0% | 3.8% | 312.0% | 0.3% | 187.1% | 3.6% |
| — | -72.1% | -87.9% | -26.6% | -5.0% | -19.2% | -50.9% | -62.0% | +5326.5% | -18.8% | +9213.4% | -97.7% | -98.6% | -98.6% | -76.4% | +82.2% | +6.6% | +101.6% | -78.4% | +3154.2% | +17.9% | |
| ROIC | 9.1% | 0.5% | 0.1% | 2.6% | 3.3% | 3.4% | 3.6% | 4.0% | 3.9% | 4.4% | 7.6% | 10.1% | 0.1% | 5.4% | 0.1% | 453.2% | 5.5% | 330.9% | 3.2% | 257.0% | 3.8% |
| — | -85.3% | -97.7% | -35.7% | -17.2% | -21.5% | -52.0% | -60.7% | +7462.6% | -18.8% | +7815.6% | -97.8% | -99.1% | -98.4% | -97.0% | +76.4% | +43.7% | +77.5% | +16.1% | +297.2% | +7.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q1 '27 | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.20 | 0.19 | 0.20 | 0.18 | 0.16 | 0.14 | 0.14 | 0.16 | 0.16 | 0.10 | 0.07 | 0.07 | 0.05 | 0.05 | 0.06 | 0.08 | 0.08 | 0.12 | 0.18 | 0.15 | 0.16 |
| — | +35.3% | +46.6% | +13.5% | +3.0% | +32.1% | +94.4% | +114.4% | +200.2% | +104.0% | +22.4% | -7.6% | -37.6% | -58.5% | -67.2% | -45.9% | -49.1% | -34.3% | +1.4% | +22.8% | -0.8% | |
| Debt / EBITDA | 1.07 | 24.21 | 12.35 | 3.51 | 2.59 | 2.19 | 2.11 | 2.18 | 2.25 | 1.41 | 1.07 | 0.01 | 59.71 | 0.59 | 70.00 | 0.01 | 0.90 | 0.02 | 2.87 | 0.03 | 2.26 |
| — | +1007.1% | +486.5% | +61.1% | +15.1% | +55.0% | +96.5% | +19119.5% | -96.2% | +139.0% | -98.5% | +4.6% | +6569.6% | +2785.1% | +2337.5% | -65.1% | -60.4% | -56.6% | -4.2% | -39.9% | +0.2% | |
| Current Ratio | 1.80 | 1.90 | 1.80 | 1.88 | 1.85 | 1.89 | 1.92 | 1.92 | 1.92 | 2.55 | 2.58 | 2.55 | 2.59 | 2.60 | 2.38 | 2.30 | 2.19 | 1.98 | 1.93 | 1.99 | 1.90 |
| — | +0.5% | -6.0% | -2.0% | -3.5% | -25.7% | -25.7% | -24.7% | -25.8% | -2.1% | +8.6% | +10.5% | +17.9% | +31.5% | +23.0% | +15.6% | +15.4% | +14.1% | +8.8% | +10.4% | +10.6% | |
| Quick Ratio | 1.35 | 1.39 | 1.35 | 1.38 | 1.35 | 1.36 | 1.37 | 1.37 | 1.36 | 1.90 | 1.92 | 1.90 | 1.91 | 1.95 | 1.81 | 1.72 | 1.58 | 1.41 | 1.39 | 1.40 | 1.32 |
| — | +2.1% | -2.0% | +0.4% | -0.9% | -28.2% | -28.5% | -27.6% | -28.8% | -2.9% | +6.0% | +10.3% | +21.0% | +38.7% | +30.1% | +22.8% | +19.6% | +19.4% | +13.0% | +16.1% | +10.7% | |
| Interest Coverage | 15.66 | 2.35 | 2.88 | 15.24 | 21.23 | 23.95 | 31.57 | 23.91 | 26.32 | 29.95 | 28.01 | 47.34 | 0.67 | 3907.82 | 0.46 | 40.11 | 0.66 | 43.23 | 0.11 | 46.16 | 0.73 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RDY stock.
Dr. Reddy's Laboratories Limited's current P/E is 21.9x. The average P/E over the last 4 quarters is 0.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Dr. Reddy's Laboratories Limited's current operating margin is 13.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Dr. Reddy's Laboratories Limited's business trajectory between earnings reports.